Ares Genetic Launches Early Access Program for its Antibiotic Susceptibility Test

  06 November 2019

Ares Genetics, a subsidiary of molecular microbiology diagnostics and syndromic testing company Curetis, has launched an early access program for its molecular antibiotic susceptibility test (AST), that leverages next-generation sequencing (NGS) and artificial intelligence (AI) technologies.

According to the company, the new test has multiple applications ranging from identifying antibiotic susceptibility in the clinical setting and for broader public health applications, as well as for drug developers looking to bring new treatments to market targeting infrectious diseases.

Further reading: Clinical Omics
Author(s): Clinical Omics
Smart Innovations  

Display your AMR technology / product:

Global AMR Technologies Database

  • Preventive – Diagnostic – Antimicrobial technologies
  • Academia – Research Institutes – Start ups – SMEs – Multinationals
  • Early research <-> near market
  • Global reach for funding / co-development / licensing
Display your technology and make use of the Continuous AMR Partnering Initiative >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!